The Nyrada share price rocketed 34% yesterday on promising preclinical trial results

Biotech company and ASX newcomer Nyrada Inc (ASX: NYR) saw its share price soar 34% yesterday after announcing encouraging preclinical results for its cholesterol-lowering drug.

The Nyrada Inc (ASX: NYR) share price hit its highest ever price of 37 cents yesterday before settling to 24 cents, which put it up 34.29% for the day.

The soaring gains are welcome news for the biotechnology company which, since listing in January this year, has seen its share price steadily fall.

What did Nyrada announce?

Yesterday morning Nyrada's share price was sent flying as it announced encouraging preclinical results from its cholesterol-lowering drug study.

The company reported that its Nyrada PCSK9 inhibitor demonstrated equivalency to 2 already approved monoclonal antibodies in healthy white blood cells. The results confirmed that the drug had potential to be used with and without statin. It is encouraging news for Nyrada as it seeks to replace expensive ongoing injections for patients with high cholesterol with the first ever oral pill.

Nyrada also announced that sales for current drugs in this field, Amgen Repatha and Rengeneron/Sanofi Praluent were in excess of US$900 million in FY2019, suggesting a potential market size.

The study that used healthy donor white blood cells treated with Nyrada's PCSK9 inhibitor NYX-PCSK9i showed an increase in LDL receptor levels and demonstrated that it was as efficient as the current injectables in the market.

Commenting on the results, CEO James Bonnar stated:

Having a drug candidate that works as well as the two market-leading monoclonal PSCK9 antibodies in a human cell model is a huge achievement. It represents a big step forward in our mission to develop the first-ever small molecule PCSK9 inhibitor to treat high cholesterol and provide a compelling cost-competitive and convenient treatment alternative to Repatha and Praluent.

What does Nyrada do?

Nyrada is a new US biotech located in Delaware, USA. It is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory diseases. Apart from the drug mentioned above, Nyrada is also researching a drug to treat brain injury, specifically traumatic brain injury and stroke.

Nyrada maintains a solid cash position, with $6.1 million in the bank as of the end of March 2020. Nyrada reports it is also largely unaffected by the impact of COVID-19, although the company is taking precautionary steps to help quarantine its business from any global fallout.

With yesterday's gains, the Nyrada share price now sits at 24 cents per share.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

Sad man sitting at desk and grabbing his head as he looks at a laptop.
ASX Share Market News

5 things to watch on the ASX 200 on Thursday

Investors might want to load their PlayStations and avoid another potential red day on the market today.

Read more »

A young well-dressed couple at a luxury resort celebrate successful life choices.
Opinions

My 3 biggest ASX portfolio winners and the one I'm buying more of

These businesses have significant growth potential.

Read more »

A man rests his chin in his hands, pondering what is the answer?
ASX Share Market News

Think you know the ASX? Try guessing the top 20 ASX shares of the past 20 years

Alongside the familiar names sit a couple of surprising names whose massive gains were supercharged by where they started two…

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Opinions

3 reasons why I think this leading ASX 200 share is a buy

This underrated business could be a top buy today…

Read more »

Man in shirt and tie falls face first down stairs.
Record Lows

I think this ASX 200 stock looks like a bargain after hitting an all-time low: Here's why

The ASX shares fell another 8% on Tuesday.

Read more »